Groundbreaking neurostimulation technology offers hope and healing for difficult-to-manage pain. Chronic low back pain, a formidable foe causing disability and soaring healthcare costs, now faces a ...
Mainstay Medical Holdings plc has won U.S. FDA approval for its Reactiv8 implantable neurostimulation device. The company is eyeing a commercial launch of the system in early 2021. The FDA approved ...
The Food and Drug Administration (FDA) has approved ReActiv8® (Mainstay Medical), an implantable neurostimulation system, for the treatment of intractable chronic low back pain. Specifically, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results